Sangamo BioSciences Appoints H. Stewart Parker to its Board of Directors

   Sangamo BioSciences Appoints H. Stewart Parker to its Board of Directors

PR Newswire

RICHMOND, Calif., June 19, 2014

RICHMOND, Calif., June 19, 2014 /PRNewswire/ --Sangamo BioSciences, Inc.
(NASDAQ: SGMO) announced the appointment of H. Stewart Parker to the Company's
Board of Directors. Ms. Parker, who founded and served as President and CEO of
Targeted Genetics Corporation, brings more than 30 years of experience in the
biotechnology industry, including 16 years of specific experience in cell and
gene therapy.

Sangamo BioSciences, Inc.

"We are very pleased to bring Stewart onto our Board during such an important
stage in Sangamo's development," said Edward Lanphier, Sangamo's president and
CEO. "As we expand our manufacturing capabilities and advance ZFP
Therapeutic^® programs for the development of genetic cures for monogenic
diseases, Stewart's proven entrepreneurial and executive leadership skills and
extensive experience in AAV gene therapy, particularly cGMP manufacturing and
clinical development, will be very valuable to Sangamo."

Ms. Parker most recently served as CEO of The Infectious Disease Research
Institute (IDRI), a non-profit global health research institute developing
vaccines and diagnostics for neglected diseases. Prior to joining IDRI in
March 2011, she was President and CEO, and a board member of Targeted Genetics
Corporation, a publicly traded Seattle-based gene therapy company, from its
inception in 1992 until November 2008. As a founder of Targeted Genetics, she
led the company to become a world leader in AAV gene therapy and the
development of gene-based treatments for acquired and inherited diseases.

Ms. Parker began her biotechnology career in 1981 with Immunex Corporation as
its first employee, and, over a 10 year period, held positions of increasing
responsibility, including Vice President of Corporate Development. While at
Immunex, she established and managed various functions across business
development, corporate communications and operations, and her efforts and
tenure ultimately contributed to the company's acquisition by Amgen in 2002.
From 1991 to 1992, she served as President and CEO and a member of the board
of directors of Receptech Corporation, a publicly traded company formed to
accelerate the development of Immunex cytokine receptor products.

"Sangamo's precise and powerful ZFP technology platform can be applied in both
genome-editing and gene regulation applications to provide potentially
curative outcomes for a range of monogenic diseases," said Ms. Parker. "I look
forward to contributing my gene therapy knowledge and expertise, and working
with the board and the rest of the Sangamo team to drive innovative ZFP
Therapeutic programs toward commercialization."

Ms. Parker currently serves as a member of the board of directors for various
for-profit and non-profit companies including C3 Jian, Inc., Oncogenex
Technologies, Inc., and IDRI. She also serves on the advisory board of the
University of Washington Foster School of Business and College of Arts &
Sciences. Parker received her MBA in Finance and International Business and
her BA from the University of Washington.

About Sangamo
Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures™for
monogenic and infectious diseases by deploying its novel DNA-binding protein
technology platform in therapeutic gene regulation and genome editing. The
Company has ongoing Phase 2 clinical trials to evaluate the safety and
efficacy of a novel ZFP Therapeutic^® for the treatment of HIV/AIDS (SB-728-T)
and NGF-AAV for Alzheimer's disease (CERE-110). Sangamo's other therapeutic
programs are focused on monogenic and rare diseases. The company has formed a
strategic collaboration with Shire International GmbH to develop therapeutics
for hemophilia, Huntington's disease and other monogenic diseases, and with
Biogen Idec for hemoglobinopathies, such as sickle cell disease and
beta-thalassemia. It has also established strategic partnerships with
companies in non-therapeutic applications of its technology, including Dow
AgroSciences and Sigma-Aldrich Corporation. For more information about
Sangamo, visit the Company's website at

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

This press release contains forward-looking statements regarding Sangamo's
current expectations. These forward looking statements include, without
limitation, references to the research and development of ZFP TFs and ZFNs,
manufacturing capability, clinical trials, therapeutic applications and
commercialization of Sangamo's ZFP technology platform, and election of
directors. These statements are not guarantees of future performance and are
subject to certain risks, uncertainties and assumptions that are difficult to
predict. Factors that could cause actual results to differ include the early
stage of ZFP Therapeutic development, uncertainties related to the timing of
initiation and completion of clinical trials, and whether clinical trial
results will validate and support the safety and efficacy of ZFP Therapeutics.
Further, there can be no assurance that the necessary regulatory approvals
will be obtained or that Sangamo will be able to develop commercially viable
gene based therapeutics. Actual results may differ from those projected in
forward-looking statements due to risks and uncertainties that exist in the
company's operations and business environments. These risks and uncertainties
are described more fully in Sangamo's Annual Reports on Form 10-K and
Quarterly Reports on Form 10-Q as filed with the Securities and Exchange
Commission. Forward-looking statements contained in this announcement are made
as of this date and will not be updated.


SOURCE Sangamo BioSciences, Inc.

Contact: Sangamo BioSciences, Inc.: Elizabeth Wolffe, Ph.D., 510-970-6000,
x271,, or Varant Shirvanian, 510-970-6000, x205,
Press spacebar to pause and continue. Press esc to stop.